Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback